Polypharmacy in Heart Failure with CKD: Prioritizing Medication-Related Problems
R.M. is a 78-year-old woman referred for a comprehensive medication review. Problem list: HFrEF (EF 35%), stage 3b CKD (eGFR 38 mL/min/1.73 m²), atrial fibrillation on warfarin, type 2 diabetes (A1c 8.4%), and knee osteoarthritis. Current medications: lisinopril 20 mg daily, carvedilol 12.5 mg twice daily, spironolactone 25 mg daily, furosemide 40 mg daily, warfarin 5 mg daily (INR 2.9 one week ago), metformin 1000 mg twice daily, glipizide 10 mg daily, naproxen 500 mg twice daily, omeprazole 20 mg daily, atorvastatin 40 mg daily, amitriptyline 25 mg at bedtime, and potassium chloride 20 mEq daily. She also takes OTC ibuprofen 400 mg about four days a week 'when the knees are bad.' She reports two falls in three months, dizziness on standing, and a home glucose log showing three readings in the 50s in the past month.
1. Identify the three highest-priority medication-related problems and justify each with patient-specific evidence from the case.
Read the worked answer
1. NSAID use in HFrEF + CKD 3b + warfarin (highest priority). She is on both prescription naproxen and OTC ibuprofen - a therapy duplication that also signals a reconciliation failure. NSAIDs cause sodium and water retention (destabilizing HF), blunt the effect of lisinopril, furosemide, and spironolactone, and precipitate AKI and hyperkalemia in a patient with eGFR 38 already on an ACE inhibitor plus an MRA plus potassium supplementation. Additive antiplatelet effect and GI mucosal injury raise bleeding risk on warfarin.
2. Hypoglycemia risk with a mismatched glycemic goal. Three readings in the 50s on glipizide plus metformin indicates overtreatment, not undertreatment, even though A1c is 8.4% (the A1c is likely inflated by anemia/illness and does not outweigh documented lows). In a 78-year-old with HF, CKD, and falls, a less stringent A1c target (~7.5–8.0%) is appropriate, and sulfonylureas in CKD carry prolonged hypoglycemia risk.
3. Fall and orthostasis cluster. Amitriptyline is a strongly anticholinergic, sedating tricyclic that is generally avoided in older adults; combined with carvedilol, furosemide, lisinopril, and spironolactone it compounds orthostatic hypotension. Two falls in three months makes this actionable, not theoretical.
2. Sequence your interventions for the next 24–72 hours. What do you change or stop first, and what exactly do you request from the prescriber?
Read the worked answer
Sequencing matters more than completeness - changing five things at once makes attribution impossible and risks new harm.
Step 1 (same day, phone call): Stop naproxen and OTC ibuprofen. This is the single change with the broadest downstream benefit (HF, renal function, potassium, bleeding). Recommend acetaminophen (capped at 3 g/day) and/or topical diclofenac as substitutes, and note that his/her knees should be reassessed non-pharmacologically.
Step 2 (same call or fax): Report the glucose log with the 50s, request a glipizide dose reduction or discontinuation, and ask for an agreed individualized A1c target documented in the chart.
Step 3 (planned, not urgent): Propose an amitriptyline taper (do not stop abruptly) with a non-anticholinergic alternative for sleep/pain, and flag it as a fall-risk contributor.
Step 4 (deliberately defer): Leave the HF regimen, warfarin, and potassium alone for now - they are appropriate therapy; the NSAID removal will change the risk picture and should be reassessed first.
Give the prescriber one clear ask per problem, with the specific evidence, rather than a list of eleven medications.
3. Build the monitoring and documentation plan. What do you measure, when, and how do you close the loop?
Read the worked answer
Labs and measurements:
- INR in 3–5 days (NSAID removal plus any antibiotic or change in diet alters anticoagulant response).
- BMP (creatinine, potassium, sodium) in 1–2 weeks, since stopping the NSAID plus an ACE inhibitor/MRA combination in CKD 3b is a hyperkalemia setup either way.
- Repeat orthostatic vitals and a symptom/fall check at the one-week follow-up call.
- Glucose log review at 1–2 weeks after any sulfonylurea change.
Documentation:
- Record each problem as a discrete entry with supporting data, the recommendation made, who was contacted and when, and the prescriber's response.
- Update the personal medication list with the OTC products removed and clearly separate 'discontinued' from 'changed.'
- Include patient-facing instructions in plain language: why the ibuprofen was stopped, what to take instead, and which symptoms to report.
Closing the loop:
- Fax or portal message to the prescriber with a response deadline, then a follow-up call if no reply.
- Schedule a 30-day check to confirm the changes actually happened at the pharmacy fill level - a recommendation that never reached the bottle is not an intervention.